1. To compare the mechanisms of action of each of the molecules in the clinic (or about to go in the clinic). This was such an important point I wanted to emphasize. Did you read that article I highlighted? Very interesting.
2. In the AGM Address the CEO highlighted that full results for Neuren's Fragile X project were presented at a national neuropsychiatry meeting in April and were being prepared for submission as a peer-reviewed paper. That's certainly submitted now. Only 4-5 months before it's published. It will (a) raise the profile of the Fragile X program; (b) the company will get the information about what they're doing out to investigators, funding sources and potential partners; (c) it's a high priority for the company to move on this.
3. That Pharma are certainly aware of the latest Neuren Fragile X results and I would not be surprised if they are in discussions, even if, it's very early in the game.
Regards, Tony
NEU Price at posting:
5.1¢ Sentiment: LT Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)